I. Duran

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma.

T. Powles, G. Sonpavde, Y. Loriot, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).

R. Salazar, A. Abad, I. Durán, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

A. Carrato, C. Rodríguez-Antona, J. García-Donas, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

Keun-Wook Lee, H. Arkenau, M. Maqueda, 2023, BMC Cancer.

PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment.

A. Teule, Jaume Capdevila, I. Duran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.